Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Viridian Therapeutics (VRDN) and Select Medical (SEM)
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31
Needham Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38
Viridian Therapeutics (VRDN): A Small-Cap Biotech With Promising Clinical Results
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}